	Participant ID:	Date of Registration:	
	Local ID:	Letters:	
	Status:		
Γ	Site:		

## **Pre-Randomization Exit Form**

* These fields are required in order to SAVE the form				
* These fields are required in order to COMPLETE the form				
Date of Visit:   *   Date  Date				
Interviewer User ID: *				
A. DATE				
1. Date Screening Discontinued: ▼				
B. REASON FOR STUDY INELIGIBILITY				
2. Mark the reason(s) for discontinuing the screening process:				
Subject has diabetes.				
Subject is <18yo and has a screening random glucose > 200mg/dL				
□ Subject has Lymphopenia (< 1000 lymphocytes/µL)				
Subject has Neutropenia (< 1500 PMN/ μL)				
Subject has Thrombocytopenia (< 150,000 platelets/ μL)				
Subject has Anemia (Hgb < 10 grams/deciliter [g/dL])				
Subject has total bilirubin > 1.5 x upper limit of normal (ULN).				
☐ Subject has AST or ALT > 1.5 x ULN.				
$\square$ Subject has INR > 0.1 above the upper limit of normal at the Center's laboratory.				
☐ Subject has a chronic active infection other than localized skin infections				
Subject has a positive PPD test result.				
Subject has had a vaccination with a live virus within 8 weeks of randomization				
☐ Subject has had a vaccination with a killed virus within 4 weeks of randomization.				
☐ Subject has had a history of infectious mononucleosis within the 3 months prior to enrollment.				
☐ Subject has laboratory or clinical evidence of acute infection with EBV or CMV.				
☐ Subject has serologic evidence of current or past HIV, Hepatitis B or C infection.				
Subject has chronic use of steroids or other immunosuppressive agents.				
Subject has a history of asthma or atopic disease requiring chronic treatment.				
Subject has untreated hypothyroidism or Graves' disease at randomization.				
Subject is currently using non-insulin pharmaceuticals to affect glycemic control.				
Subject has had prior OKT®3 treatment or other anti-CD3 treatment.				
Subject has had prior administration of a monoclonal antibody within the previous 1 year before randomization.				
Subject is currently participating or previously participated in a therapeutic drug or vaccine clinical trial within the last 12 weeks.				
☐ Subject has a condition, in the opinion of the investigator, that would interfere with the study conduct or the safety of the subject.				
Subject is sexually active and refuses to use an effective form of birth control.				
Subject has reproductive potential and refuses to promptly report possible or confirmed pregnancies during the course of the study.				
Subject is not willing to avoid pregnancy (if male, in any partners) for at least one year from randomization.				
If female:				
☐ Subject has reproductive potential and refuses to undergo pregnancy testing during the course of the study.				

Subject is currently pregnant or less than three months postpartum.	
Subject is currently lactating.	
Subject refused or did not complete the pregnancy test at this visit.	

Save Print Close Window